

Index

A

- Abstinence, 10, 25, 70, 85, 101, 151
 - adolescents and abstinence programs, 249
 - candidates and counseling, 248–249
 - sexual, 260
- ACOG. *See* American College of Obstetrics and Gynecology (ACOG)
- Actinomyces* species, 172
- Adiana permanent contraception system, 232–233
- The Affordable Care Act, 135
- American Academy of Pediatrics (AAP), 65
- American College of Obstetrics and Gynecology (ACOG), 24, 45, 65, 272
- Area under the curve (AUC), 89

B

- Barrier contraceptive methods
 - combined, 182
 - first-year failure rates, 182, 184
- Barrier methods, 22
- Basal body temperature (BBT), 255, 257
- Behavioral methods
 - abstinence, 248–249
 - Coitus interruptus*, 249–251
 - contraception resources, 258
 - FAM, 248
 - fertility awareness methods, 251–260
 - menstrual cycle *See* (Menstrual cycle)
 - NFP, 248
- Bone mineral density (BMD), 129–130
 - ACOG, 272
 - DEXA, 270–271

- DMPA, 270–271
- FDA, 270
 - progestin effects, 269
- Breast cancer risk
 - BRCA1/BRCA2* mutations, 265
 - COC, 265
 - family history, 265–266
 - personal history, 266
 - VTE, 266–269
 - in women, 266
- Brundin P-block, 240

C

- Calendar/rhythm method, 252–253
- Cervical cap. *See* FemCap®
- Cervical mucus methods
 - Billings technique, 255
 - two-day method, 256
- CHC. *See* Combined hormonal contraceptives (CHC)
- ClearBlue™, 257
- COCs. *See* Combination oral contraceptive pills (COCs)
- Coitus interruptus*
 - candidates, 250
 - drawbacks, 250
 - effectiveness, 250
 - noncontraceptive benefits, 250
 - patient education, 251
- Combination oral contraceptive pills (COCs)
 - abnormal bleeding/spotting, 71
 - adolescents, 64
 - advantages and disadvantages, 72–73
 - arterial and venous thrombosis, 62

- Combination oral contraceptive pills (COCs)
 - (*cont.*)
 - arterial thromboembolism, 115
 - bleeding pattern, 113
 - bleeding problems, 20
 - BRCA carriers, 265
 - cancer risk, 30
 - carcinoma, 96
 - clinical effectiveness, 64
 - contraindications, 118
 - counseling tips, 71
 - drospirenone, 62
 - and drug interactions, 67
 - estrogen and progestin, 62
 - ethinyl estradiol (EE), 62
 - extended-cycle, formulations, 62
 - fertility delay, 96
 - LARC, 65
 - light/missing periods, 72
 - mechanism, 64–65
 - missing placebo pills, 72
 - multiphasic formulations, 62
 - noncontraceptive health benefits, 69–70
 - perimenopausal symptoms, 30
 - and POPs, 80
 - progestins, 63, 64–65
 - “quick start” method, 70
 - safety of contraceptives, 66
 - “Sunday start” method, 70
 - US MEC, 66–68
- Combination oral contraceptives (COCs), 126, 131, 204
- Combined hormonal contraceptives (CHC)
 - arterial thromboembolism, 115
 - estrogen, 49
 - steroid hormones, 49
 - tobacco smoking, 53–54
 - US MEC, 53
- Contraceptive diaphragm
 - advantages and disadvantages, 197
 - dome shaped devices, 196
 - fitting, 196
 - history of birth control in USA, 195
 - mechanism, 196
 - oral contraceptives and IUDs, 195
 - patient counseling, 197
 - SILCS diaphragm, 198
 - types, 196
- Contraceptive effectiveness
 - accidental pregnancy, 3
 - condoms, 9
 - contraceptive pills, patches and rings, 18
 - counseling experience, healthcare provider, 11
 - “cumulative failure rate”, 4
 - depot medroxyprogesterone acetate, 8
 - etonogestrel subdermal implant, 8
 - family planning methods, 11, 12
 - female barrier methods, 9–10
 - female sterilization, 7
 - fertility awareness methods, 10
 - influence efficacy rate, 4–5
 - IUD, 7–9
 - male sterilization, 7
 - Pearl Index, 3–4
 - pregnancy rates, 5
 - qualitative contraceptive research, 11
 - spermicides, 10
 - vs. efficacy, 2
- Contraceptive sponge
 - advantages and disadvantages, 199
 - efficacy, 198
 - Today[®] sponge, 198
 - in the US market, 183
 - vaginal barrier with spermicide, 198
- Contraceptive vaginal ring (CVR)
 - advantages
 - bleeding pattern, 113
 - discrete, 113
 - dosing schedule, 112–113
 - non-contraceptive benefits, 113
 - arterial thromboembolism, 115
 - cancer risk, 116
 - clinical effectiveness, 111–112
 - continuation, 112
 - contraindications, 118
 - counseling and patient selection, 118–120
 - counseling tips, 120
 - disadvantages, 113
 - disease control and prevention, 117, 118
 - drug delivery, 118
 - EVA, 108
 - hyperlipidemia, 116
 - instructions to use, 119
 - mechanism of action, 111
 - menopausal estrogen replacement, 108
 - pharmacokinetics, 109–111
 - poor candidates, 120
 - Population Council and HRA Pharma, 108
 - pregnancy, 119
 - reproductive effects, 116
 - side effects, 113–114
 - switching, 119
 - and VTE, 114–115
 - weight gain, 115–116
- Copper IUD (ParaGard[®]), 212
- Correct contraceptive method
 - birth control type, 25

diaphragm and cervical caps/shields, 29
 DMPA and depo-subQ provera 104™, 27–28
 emergency contraception, 29
 IUD, 26
 male and female condom, 26
 oral contraceptives, patch/ring, 26
 subdermal progestin implant, 26
 The Cupid FC®, 193

D

Deep venous thrombosis (DVT), 52–53, 67, 71, 84, 98, 117
 Depo-Provera®, 126
 Depo-subQ and progestin-only pill/mini-pills, 22
 Depo-subQ provera 104 (depo-subQ), 27–28
 Depot medroxyprogesterone acetate (DMPA), 8
 absolute (USMEC category 4), 132
 17-acetoxy-6-methyl progestin, 135
 advantages, 130, 272
 assessments, 170
 bleeding, 134
 BMD, 130
 BMD test, 270
 bone loss, 28
 breast cancer risk, 31–34
 cardiovascular risk, 131
 clinical effectiveness, 134–135
 contraceptive agent, 126
 contraceptive-linked benefits, 128
 contraindications, 131
 cost and insurance issues, 135
 counseling, 132
 Depo-Provera®, 126
 disadvantages, 128–129
 drug interactions, 129
 endometriosis-associated pain, therapeutic effect, 135
 good candidates, 126
 gynecological conditions, 126
 hypoestrogenic effects, 131
 instructions, 132
 noncontraceptive benefits, 128
 ovulation resumption, 275
 poor candidates, 127
 relative (USMEC category 3), 131–132
 repeat injections, 134
 reproductive effects, 129
 screening tests, 133
 sexually transmitted infection risk, 130
 side effects, 132, 134
 skeletal health, 129–130
 VTE, 131

warning signals, 129
 and weight gain, 129, 134
 women, ages, 126
 DEXA. *See* Dual-energy X-ray absorptiometry (DEXA)
 Diaphragm. *See* Contraceptive diaphragm
 DMPA. *See* Depot medroxyprogesterone acetate (DMPA)
 Dual-energy X-ray absorptiometry (DEXA), 270–271
 DVT. *See* Deep venous thrombosis (DVT)

E

ECs. *See* Emergency contraceptives (ECs)
 Ectopic pregnancy and IUC, 172
 EE. *See* Ethinyl estradiol (EE)
 Electronic hormonal fertility monitors (EHFM), 256
 Emergency contraceptives (ECs)
 advantages of, 207
 COCs, 204
 common side effects, 209
 copper IUD (ParaGard®), 207, 211, 212
 counseling, 210–211
 disadvantages, 207–208
 ectopic pregnancy, 209
 effectiveness, 206–207
 fetal effects, 210
 hormonal EC pills, 206
 hormonal options, 204
 indications, 208
 IUD, 204
 LNG, 204
 medical contraindications, 209–210
 menses, effect, 208–209
 practice agreement in states, 205
 PRM, 204
 product repackaged, 211
 professional organizations, 205
 unintended pregnancy, 204
 Endometrial ablation, 233
 Endometrial hyperplasia, 171
 Endometriosis and pelvic pain, 171
 Essure® micro-insert, 231–232
 Ethinyl estradiol (EE)
 cardiovascular events and stroke, 97
 and COCs, 61
 gestrodene, 91
 and NGM, 89
 pharmacokinetics, 109–111
 and TDS, 89
 thrombotic events, 95
 and VTE, 114
 Ethylene vinyl acetate (EVA), 108

F

FAM. *See* Fertility awareness methods (FAM)

Female condom (FC2)

- advantages, 192
- disadvantages, 192
- efficacy, 191
- patient counseling, 192–193
- silicone-based lubricant, 191
- single-size, disposable condom, 191

Female tubal sterilization

- approaches, 218–219
- Brundin P-block, 240
- chemical agents, 237
- Hamou intratubal thread, 240
- health benefits, 217
- Hosseinian uterotubal junction device, 240
- hysteroscopic approach, 239
- vs. ideal method, 216, 242
- intratubal ligation device, 241–242
- IVF, 235
- laparoscopic approach, 222–224
- microwave, 242
- OCs, 216
- postpartum sterilization, 217
- quinacrine, 237–238
- reconstructive surgery, 235–236
- regret, 234
- reversal, 234–236
- rigid ceramic plug, 240
- safety device, 236
- silicone plugs, 241
- tissue adhesives, 238
- tubal coagulation, 224

FemCap®

- advantages and disadvantages, 195
- antiretroviral medication,
 - HIV infection, 195
- description, 193
- efficacy, 194
- patient counseling, 194
- sizes for, 193

Fertile period calculation, 252

Fertility awareness methods, 10

- BBT, 255
- cervical mucus methods, 255–256
- EHFM, 256
- symptothermal technique, 256

Fertility awareness methods (FAM)

- advantages, 257
- and NFP, 248

Fertility post-IUC, 172

Formed-in-place silicone plugs, 241

G

General reproductive-aged woman

- acne/androgen excess, 19–20
- bleeding problems, 20
- cancer risk, 30
- compliance, 20
- medical problems, 20

Gestrodene (GSD), 91–92

Gynecologic cancers, 55–56

H

Heavy menstrual bleeding

- Cochrane collaborative systematic review, 170–171
- definition, 170
- LNG-20, inhibitory effects, 170

Hosseinian uterotubal junction device, 240

Hypertension, 46–48

- arterial cardiovascular disease, 67
- arterial thromboembolism, 115
- “multiple risk factors for arterial cardiovascular disease”, 46–47
- myocardial infarction and stroke, 31
- thrombophilia, 21

Hysterectomy, 233–234

I

IBD. *See* Inflammatory bowel disease (IBD)

Implanon®, 37

Implanon and Nexplanon (single-rod etonogestrel implant), 141

Implantable contraception

- adolescents, 143
- at 36, 48 and 60 months, efficacy of, 145–147
- anesthesia, 153
- backup contraception, 151–152
- candidates, 141–142
- chronic medical conditions, women with, 142–143
- counseling
 - adverse events, 149
 - BMD, 149
 - events among users, 150
 - irregular bleeding, 148–149
 - STIs, 150
- description, 140
- drug interactions, 147–148
- etonogestrel implant insertion, 146
- hormonal, 142
- imaging techniques, 158–160

- Implanon and Nexplanon (single-rod etonogestrel implant), 141
- insert implant, 154, 155
- insertion, complications of, 156
- Jadelle rod, 160
- lactating women, 143
- medical conditions, 142–143
- Norplant (two-rod levonorgestrel system), 141
- oral/injected steroids, 145
- overweight and obese women, 147
- ovulation inhibition and sperm penetration, 145
- patient positioning, 153
- pharmacology, 144
- placement, 154, 156
- postabortion/postpartum, 151
- post-insertion care and follow-up, 156
- progestin-based, effective and reversible methods, 140
- reinsertion, 160
- removal
 - anesthesia, 153–154
 - disadvantages, 158
 - model arm and manual compact disc, 157
 - procedure, 157–158
 - rod removal, 158, 159
- reproductive age, women of, 141–142
- women with unintended pregnancy, percentage of, 145, 146
- Infertility
 - COC formulations, 274
 - DMPA and weight gain, 277–278
 - hormonal methods, 276
 - intrauterine contraception and tubal, 273–274
 - ovulation, 275–276
 - weight gain, 276
- Inflammatory bowel disease (IBD), 69
- Intratubal ligation device, 241–242
- Intrauterine contraception (IUC) devices
 - ACOG, 166
 - Actinomyces* species, 172
 - acute salpingitis, treatment, 171–172
 - clinical effectiveness, 167
 - cost and insurance issues, 176
 - counseling, 173
 - device loading, 174
 - ectopic pregnancy and, 172
 - emergency contraception, 169–170
 - expulsions, 175
 - fertility post-IUC, 172
 - fertilization and implantation, 176
 - good candidates, 167–168
 - HIV disease, 169
 - inhibition of implantation, 176
 - insertions, 174
 - non-contraceptive benefits, 170–171
 - nulliparity, 168–169
 - poor candidates, 169
 - post-abortion, 168
 - postpartum, 168
 - removal, 175
 - septic abortion and pelvic infections, 169
 - side effects, management, 175
 - TCu380A IUD, LNG-20 and LNG-14, 166
 - timing of initiation, 176
- Intrauterine devices (IUD)
 - and AIDS, 54
 - bleeding problems, 19–20
 - copper T, 167–168
 - DMPA and weight gain, 277–278
 - fertility, 274–275
 - hypertension, 46–48
 - levonorgestrel, 9
 - nulliparity, 168–169
 - perimenopausal women, 32
 - quinacrine, 237–238
- In vitro fertilization (IVF)
 - advantages, 235
 - repeat operation, 236
- IUC. *See* Intrauterine contraception (IUC) devices
- IVF. *See* In vitro fertilization (IVF)
- J**
 - Jadelle rod, 160
- L**
 - Lactational amenorrhea method (LAM)
 - breastfeeding, 258
 - candidates, 259
 - drawbacks, 259
 - noncontraceptive benefits, 259
 - Laparoscopic approach
 - complications, 228–229
 - diagnostic, 223
 - electrocoagulation methods, 224–226
 - failures, 229
 - reintroduction, 223
 - trocar, 223
 - Laparoscopic clips, 227–228
 - Laparoscopic electrocoagulation methods
 - bipolar forceps, 225
 - double-burn and triple-burn approach, 226

Laparoscopic electrocoagulation methods
(*cont.*)

fallopian tubes, 224–225

monopolar tubal sterilization, 225

Laparoscopic mechanical methods, 226

Laparoscopic salpingectomy, 228

Laparoscopic silastic rings, 227

Laparotomy, 222

Levonorgestrel (LNG)

actinomyces, 172

contraceptive efficacy and safety study, 91

desogestrel transdermal system, 92

endometriosis and pelvic pain, 171

and IUDs, 21

postpartum, 168

progestin-only methods, 53

Lipid disorders (hyperlipidemia), 49

LNG. *See* Levonorgestrel (LNG)

Long-acting reversible contraceptive

(LARC), 46–47, 65

adolescent pregnancy, 23

general reproductive-aged woman, 18

sterilization, 32

Low-dose combination hormonal

methods, 33–34

M

Male condoms

advantages of, 185–186

Bill R Melinda Gates Foundation, research
projects, 187

designs and accessories, 183

disadvantages of, 186–187

efficacy, 184–185

ejaculation and secretions, 183–184

encouraging developments, 189

instructions, 188–189

“lambskin”/“natural membrane”, 184

latex condoms, 184

lubricants, 184

patient counseling, 187–188

polyurethane, 184

risk of pregnancy, reduction, 185

STD risk reduction, 183

Menstrual cycle

candidates, 251

effectiveness and continuation rates,
251–252

FAM and NFP, 251

natural family planning, 252–253

Microwave sterilization, 242

Milex Wide-Seal Arcing Style Diaphragm, 196

Milex Wide-Seal OmniFlex Diaphragm, 196

Minilaparotomy, 221–222

N

Natural family planning (NFP), 248, 251–253

adolescents, 23–24

calendar/rhythm method, 252–253

counseling, teenager, 24–25

CycleBeads™, 253–254

fertile period calculation, 252

Norplant (two-rod levonorgestrel system),
140–141

O

OvaCue™ fertility monitor, 257

P

PE. *See* Pulmonary embolism (PE)

Pearl Index, 2–3

Perimenopausal women

barrier methods, 32

bleeding problems, 30

BMD, 30–31

breast cancer risk, 31

cancer risk, 30

cardiovascular risks, 31

clotting problems, 35

contraindications, older population, 34

emergency contraception, 33

evaluation, 34

fertility, 29

hormone therapy, 35

IUDs, 32

low-dose combination hormonal methods,
33–34

menstrual bleeding patterns and “roller-
coaster” changes, 29

NFP, 33

noncontraceptive benefits, 35

reproductive-age women, 29

sterilization, 32

symptoms, 30

Persona™, 257

Pharmacokinetics

CVR, 109

ethinyl estradiol, 109

3-keto-desogestrel, 111

serum hormone levels, 110

pH-based spermicide—Amphora™, 200

Phoenurse FC®, 193

POPs. *See* Progestin-only pills (POPs)

Post-abortion methods, 221

Postpartum methods

fimbriectomy, 220

interval methods, 221

laparoscopic approach, 222–228

- laparotomy, 221
 - minilaparotomy, 221–222
 - pomeroy procedure, 219–220
 - post-abortion methods, 221
 - salpingectomy, 219–220
 - sterilization, 218
 - vaginal approach, 222
 - Pregnancy and lactation
 - barriers, 38
 - Implanon[®], 37
 - IUD, 37
 - timing of initiation, 37–38
 - tubal ligation and fallopian tube micro-insert, 38
 - Progesterone receptor modulator (PRM), 204
 - Progestin-only levonorgestrel (LNG) EC pills, 204
 - Progestin-only pills (POPs)
 - advantages, 81–82
 - clinical effectiveness, 85
 - cost and insurance issues, 86
 - counseling tips, 84–85
 - disadvantages
 - drug interactions, 83
 - reproductive effects, 83
 - serious side effects, 82
 - side effects, 82
 - good and poor candidates, 81
 - managing side effects, 85
 - mechanism, 85–86
 - precautions/contraindications, 83–84
 - progestin and norethindrone, 80–81
 - Progestins. *See* Depot medroxyprogesterone acetate (DMPA)
 - Progestin therapy, 171
 - Pulmonary embolism (PE), 52–53
- Q**
- Quinacrine, 237–238
- S**
- Salpingectomy, 7, 219–220. *See also* Laparoscopic salpingectomy
 - Sexually transmitted disease (STD)
 - treatment guidelines, 183
 - Sexually transmitted infections (STIs), 130, 150
 - SLE. *See* Systemic lupus erythematosus (SLE)
 - Solid organ transplantation, 56
 - Spermicides, vaginal
 - advantages and disadvantages, 200
 - developments, 200
 - efficacy, 200
 - upper genital tract, 199
 - in the USA, 199–200
 - STIs. *See* Sexually transmitted infections (STIs)
 - Subdermal implant Nexplanon, 21
 - Symptothermal technique, 256
 - Systemic lupus erythematosus (SLE), 53
- T**
- TC-based CooperSurgical, Inc., 196
 - TDS. *See* Transdermal contraceptive system (TDS)
 - Tobacco smoking, 53–54
 - Traditional sterilization methods
 - approaches, 218
 - postpartum methods, 218–219
 - Transcervical approach
 - adiana permanent contraception system, 232–233
 - advantages, 230–231
 - disadvantages, 231
 - endometrial ablation, 254
 - Essure[®] micro-insert, 231–232
 - hysterectomy, 254–255
 - Transdermal contraceptive system (TDS)
 - absolute contraindications, 97–98
 - advantages, 93–94
 - cardiovascular events and stroke, 96
 - clinical effectiveness, 102
 - cost and insurance issues, 103
 - counseling tips, 99–100
 - desogestrel transdermal system, 92
 - disadvantages, 94
 - drug interactions, 96
 - EE/NGM, 96
 - gestrodene, 91–92
 - good and poor candidates, 92–93
 - instructions to use, 100
 - levonorgestrel and ethinyl estradiol, 90–91
 - levonorgestrel transdermal system, 92
 - managing side effects, 102
 - mechanism, 102
 - norethindrone acetate transdermal system, 92
 - relative contraindications, 98–99
 - reproductive effects, 96–97
 - side effects, 94–95
 - thrombotic events, 95
 - timing of initiation, 101
 - warning signals, 96

U

- Unscheduled bleeding
 - discontinuation, 149
 - endogenous estrogen production, 148
 - intervals and menstrual bleeding patterns, 148
 - management of, 149
 - mean number of, 149
- USMEC. *See* The U.S. Medical Eligibility Criteria for Contraceptive Use (USMEC)
- The U.S. Medical Eligibility Criteria for Contraceptive Use (USMEC), 60, 131–132
 - breast cancer, 55
 - headache, 51
 - HIV/AIDS, 54
 - hyperlipidemia, 49
 - hypertension, 46–47
 - numerical and color-coded labeling system, 45
 - smoking, 56
 - US SPR, 45
- US Selected Practice Recommendations (US SPR), 44, 45

V

- Vaginal barriers
 - cervical cap, 193–194
 - contraceptive diaphragm, 195–198
 - contraceptive sponge, 198–199
 - FC2, 191–194

- spermicides, 199–200
- types, 191, 192
- VA W.O.W.[®] (worn of women) Feminine Condom[®], 193
- Venous thromboembolism (VTE)
 - COCs, 267–268
 - estrogen, 267
 - hormonal contraception, 269
 - thrombophilia and hormonal contraception, 269

W

- The Woman's Condom[®], 193
- Women, medical conditions
 - “causing any harm”, 46
 - diabetes, 48–49
 - DVT/PE, 52–53
 - gynecologic cancers, 55–56
 - headache, 51–52
 - health risks, pregnancy, 47
 - HIV/AIDS, 54
 - hypertension, 46–47
 - lipid disorders (hyperlipidemia), 49
 - male condoms, 46
 - obesity, 49–50
 - reproductive life planning, 44
 - resources, 44
 - sexually active woman, 46, 47
 - solid organ transplantation, 56
 - tobacco smoking, 53–54
 - US MEC, 44–45
 - US SPR, 45